survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma

M Ikeguchi* and N Kaibara1

1First Department of Surgery, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan

Oesophageal squamous cell carcinoma is one of the most malignant tumours. To identify patients with a high risk of recurrence of oesophageal squamous cell carcinoma, we investigated the prognostic significance of survivin mRNA expression in oesophageal squamous cell carcinoma, which has recently been reported to be a good marker for unfavourable prognosis in various tumours. Tumours and non-cancerous epitheliums adjacent to tumours were obtained by surgical resection from 57 patients with oesophageal squamous cell carcinoma. Expression levels of survivin and glyceraldehyde-3-phosphate dehydrogenase mRNA were analysed quantitatively by real-time reverse transcriptase polymerase chain reaction (RT–PCR). The survivin/glyceraldehyde-3-phosphate dehydrogenase ratios of tumours were higher than those of non-cancerous tissues (P=0.0003). Tumour-survivin/glyceraldehyde-3-phosphate dehydrogenase ratio did not correlate with histologic type, lymph node metastasis, and stage of tumours. In 53 surviving patients, the 5-year survival rate of 17 patients with high survivin mRNA expressed oesophageal squamous cell carcinoma (14.1%) was significantly poorer than that of 36 with low survivin mRNA expressed oesophageal squamous cell carcinoma (46.8%, P=0.0018). In these patients, tumour-survivin mRNA expression was recognised as a good marker of cancer recurrence independently from tumour stage. These findings indicate that survivin mRNA expression in oesophageal squamous cell carcinoma may be a good biomarker for identifying patients with high risk of cancer recurrence.

British Journal of Cancer (2002) 87, 883–887. doi:10.1038/sj.bjc.6600546 www.bjcancer.com

Keywords: oesophageal squamous cell carcinoma; survivin; real-time reverse transcriptase polymerase chain reaction; prognosis
regions distant from the tumours. Half of each tissue sample was fixed in 10% buffered formalin and embedded in paraffin. Sections (4 μm thick) were prepared for hematoxylin-eosin staining for histopathologic diagnosis and for immunohistochemical staining. The other half of the tissue was stored at −80°C until needed.

Patients

The subjects (57 OSCC patients) included 54 men and three women, age at time of surgery was 65.2 ± 1.2 years (mean ± standard error; median, 67; range 45 – 84). Tumours were staged according to the TNM system. The stages of the 57 patients were I (n=8), II (n=18), III (n=26), and IV (n=5). None of the patients received preoperative chemotherapy or radiation therapy. Thoracoabdominal oesophagectomy was performed on 36 patients by right-sided antero-lateral thoracotomy and laparotomy. Intrathoracic and peri-aortic lymph nodes were dissected during this procedure. Transhiatal oesophagectomy without thoracotomy was performed on 19 patients. Lower oesophagectomy through the transabdominal approach was performed on two patients. Curative oesophagectomy was performed on 45 patients and non-curative oesophagectomy was performed on 12 patients (one: liver metastasis, three: extended lymph node metastasis, and eight: local invasion). All patients were followed until February 2002. The mean follow-up period for the 57 patients was 29.2 months (ranging from 1 – 99 months). Causes of death were determined from clinical findings. Nineteen patients were alive at February of 2002, and a total of 38 patients had died. Six patients died from diseases other than OSCC (four died from operative complications and the in-hospital mortality rate was 7%), while 32 died from recurrence or relapse of OSCC.

Detection of survivin transcripts using real-time RT–PCR

Before starting the study, histopathologic examination confirmed that there were a sufficient number of cancer cells in the tumour samples and that no cancer cells had contaminated the non-cancerous tissues. Total RNA from EC-GI-10 and tissues was isolated using RNeasy Mini Kits (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Total RNA was eluted with 50 μl of diethylpyrocarbonate (DEPC) water. RNA concentrations were determined by spectrophotometry. One microgram of the total RNA derived from the EC-GI-10 cell line. The plots represent the log of the input amount (log ng of total starting RNA) as the x-axis and Ct as the y-axis. Equations were derived from the lines of the calibration curves (Yajima et al, 1998). The formulas for survivin and GAPDH were as follows: survivin, y=28.6–3.6x (r²=0.998) and GAPDH, y=26.3–4.3x (r²=0.991) (Figure 1). For each of the experimental samples, the amount of survivin and GAPDH mRNAs were determined from the standard curves. GAPDH transcripts were monitored as a control to quantify the transcripts of the genes in each sample. The normalised amounts of survivin mRNA, respectively, were determined by dividing the amount of survivin mRNA by the amount of GAPDH mRNA for each sample.

Immunohistochemistry

To identify survivin protein expressing cells, tissue samples (tumours and non-cancerous oesophageal epithelium) were immunostained with a rabbit anti-human survivin polyclonal antibody (diluted to 1:20; Alpha Diagnostic International, San Antonio, TX, USA). After overnight incubation the slides with a primary antibody at 4°C, ENVISION+ (DAKO Japan Co. Ltd, Kyoto, Japan) was applied as the secondary antibody for 30 min.

Quantification of gene expression

Quantification of gene expression was performed by real-time quantitative RT–PCR (Gene Amp® 5700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA, USA)), which uses the 5’ nuclease activity of Taq polymerase to detect PCR amplicons (Yajima et al, 1998; Mitas et al, 2001). The PCR solution (50 μl) was composed of 1 μl of cDNA solution, 5 pmol of the forward and reverse primers, 10 pmol of internal probe, and TaqMan Universal PCR Master Mix. PCR was carried out after incubation at 50°C for 2 min, denaturing at 95°C for 10 min, 45 cycles of 95°C for 15 s, and 61°C for 1 min. Experiments were performed in duplicate for each data point. For each reaction tube, the fluorescence signal of the reporter dye (FAM) was divided by the fluorescence signal of the passive reference dye (TAMRA) to obtain a ratio defined as the normalised reporter signal (Rn). The threshold line was set at an Rn of 0.05 (10 standard deviations above the mean of the baseline fluorescence emission calculated from cycles 3–20) (Yajima et al, 1998). The point at which the amplification plot crossed this threshold was defined as Ct, which represented the cycle number at this point. Standard curves for survivin, and GAPDH were generated using serial dilution (containing 160, 80, 40, 20 and 10 ng) of total RNA derived from the EC-GI-10 cell line. The plots represent the log of the input amount (log ng of total starting RNA) as the x-axis and Ct as the y-axis. Equations were derived from the lines of the calibration curves (Yajima et al, 1998). The formulas for survivin and GAPDH were as follows: survivin, y=28.6–3.6x (r²=0.998) and GAPDH, y=26.3–4.3x (r²=0.991) (Figure 1). For each of the experimental samples, the amount of survivin and GAPDH mRNAs were determined from the standard curves. GAPDH transcripts were monitored as a control to quantify the transcripts of the genes in each sample. The normalised amounts of survivin mRNA, respectively, were determined by dividing the amount of survivin mRNA by the amount of GAPDH mRNA for each sample.

Figure 1 Standard curves for survivin and GAPDH. The plots represent the log of the input amount (log ng of total starting RNA of EC-GI-10; a: 160 ng; b: 80 ng; c: 40 ng; d: 20 ng; e: 10 ng) as the x-axis and threshold cycle (Ct) as the y-axis for survivin and GAPDH.
The reaction products were visualised with diaminobenzidine as the chromogen, and the slides were counterstained with methyl green.

**Statistical analysis**

The \( \chi^2 \) and Fishers exact probability tests were used to compare the distribution of individual variables among the patient groups. Differences in the numerical data between the two groups were evaluated using the Mann-Whitney U test. Differences in the numerical data among more than three groups were evaluated using the Kruskal–Wallis test. Survival rates were calculated using the Kaplan–Meier method. The log rank test was used for comparisons of two survival curves. A \( P \)-value of 0.05 was considered to be statistically significant.

**RESULTS**

**Survivin/GAPDH ratio in tumours and in non-cancerous tissue of the oesophagus**

The survivin/GAPDH ratio of carcinomas (mean ± standard error (s.e.): 5.3 ± 0.8, range: 0.4–37) was significantly higher than that of non-cancerous tissues (3.6 ± 0.8, range: 0–37.5, \( P=0.0003 \)). Figure 2 shows one typical case. In this case, the survivin/GAPDH ratio of the tumour tissue was 3-fold higher than that of non-cancerous tissue. A significant positive correlation between tumour-survivin/GAPDH ratios and non-cancerous tissue-survivin/GAPDH ratios was detected in 57 patients (\( r=0.413 \), \( P=0.0022 \)). However, the survivin/GAPDH ratio of tumours did not correlate with histologic type, lymph node involvement, or depth of tumour invasion (Table 1).

**Localisation of survivin protein in oesophageal tissue**

Survivin protein was detected not only in the cytoplasm, but also in nuclei of all cancer cells (Figure 3) and normal basal cells in non-cancerous epithelium. Normal basal cells showed weak survivin protein expression (Figure 4). Sixteen tumours expressed strong survivin protein, while the remaining 41 tumours expressed weak survivin protein as same level as normal basal cells. The survivin/GAPDH ratio of 16 tumours with strong survivin protein expression (11.5 ± 2.1) was significantly higher than that of 41 tumours with weak expression (2.9 ± 0.3, \( P<0.0001 \)).

**Table 1 Clinicopathological findings of patients and tumor-survivin/GAPDH mRNA ratios**

|                  | Tumor-survivin/GAPDH mRNA ratio (mean ± s.e.) | \( P \) |
|------------------|---------------------------------------------|-------|
| Histologic type of tumour |                               |       |
| Well differentiated | 2 9.2 ± 8.3                              | 0.6655 |
| Moderately differentiated | 29 4.8 ± 0.9                           |       |
| Poorly differentiated    | 26 5.6 ± 1.4                            |       |
| Lymph node metastasis   |                               |       |
| Negative                | 22 4 ± 0.8                              | 0.2828 |
| Positive                | 35 6.2 ± 1.2                            | 0.5066 |
| Invasion to adventitia   |                               |       |
| Negative                | 22 5.2 ± 0.9                            |       |
| Positive                | 35 5.4 ± 1.2                            |       |

s.e.: standard error.

**Figure 2** Amplification curves of survivin and GAPDH in a typical case. Line a: GAPDH of tumour, line b: GAPDH of non-cancerous tissue adjacent to carcinoma, line c: survivin of tumour, and line d: survivin of non-cancerous tissue. The horizontal line at \( R_n=0.05 \) is the threshold for detection.

**Figure 3** Strong survivin protein expression was detected in nuclei of all cancer cells and weak survivin expression was observed in the cytoplasm by immunostaining with a polyclonal antibody (\( \times 100 \)).

**Figure 4** Normal esophageal cells in the basal layer show weak survivin protein expression (\( \times 100 \)).
Prognostic significance of the survivin/GAPDH ratio in OSCC

We divided the 57 patients into two subgroups according to their tumour-survivin/GAPDH ratio. The cut-off value of the survivin/GAPDH ratio of tumours was decided from the formula (mean±2×s.c.) of 57 non-cancerous tissue-survivin/GAPDH ratios (Cheung and Cheung, 2001). Mean survivin/GAPDH ratio of 57 non-cancerous tissues was 3.6 and s.c. was 0.8. Thus, the calculated cut-off value of survivin/GAPDH ratio of tumours was 5.2. Eighteen tumours showed high survivin/GAPDH ratio (>5.2) and 13 of these 18 (72%) showed strong survivin protein expression by immunohistochemistry. While in 39 tumours with low survivin/GAPDH ratio (≤5.2), only three tumours (7.7%) showed strong protein expression. Figure 5 shows the survival curves of the 53 surviving patients. The survival curve of 17 patients with high-survivin/GAPDH ratio-tumours (>5.2, 5-year survival rate was 14.1%) was significantly lower than that of 36 patients with low-survivin/GAPDH ratio-tumours (≤5.2, 5-year survival rate was 46.8%, P=0.0018). In February 2002, in the 53 surviving patients, tumour recurrence or relapse was detected in 33 (62.3%) and 32 had died from OSCC. The mean tumour-survivin/GAPDH ratio of the 33 who had developed recurrent or relapsed tumours (6.3±1.2) was higher than that of the 20 without tumour recurrence or relapse (3.6±0.7, P=0.0281). The clinicopathological and the biological factors, thought to be correlated with the occurrence of cancer recurrence, were analysed. By multivariate logistic regression analysis, the tumour-survivin/GAPDH ratio was detected as a risk factor of cancer recurrence independent from depth of tumour invasion or lymph node involvement (Table 2).

In the 53 surviving patients, adjuvant radiation therapy was performed for 36 patients (total dose was 30 to 50 Grays). The 5-year survival rate of the 36 patients who underwent adjuvant radiation therapy (32.8%) was not different from that of the 17 patients who did not (45.8%, P=0.3317). The 5-year survival rates of patients with high-survivin/GAPDH ratio (with adjuvant therapy, n=8, 0%; without adjuvant therapy, n=9, 22.2%) were significantly poorer than those of patients with low-survivin/GAPDH ratio (with adjuvant therapy, n=28, 40.1%, P=0.0014; without adjuvant therapy, n=8, 72.9%, P=0.0253).

![Image](image_url)

**Figure 5**  The disease-specific survival curves of the 53 surviving patients. The survival curve of 17 with high-survivin/GAPDH ratio-tumours (line b) was significantly lower than that of 36 with low-survivin/GAPDH ratio-tumours (line a). The difference between two survival curves was statistically significant (P=0.0018).

### Table 2 Factors affecting tumour recurrence analysed by multivariate logistic regression analysis

| Variable                                      | \( \chi^2 \) | \( P \) |
|-----------------------------------------------|--------------|--------|
| Invasion to adenocitum (Positive vs Negative) | 5.007        | 0.0253 |
| Lymph node metastasis (Positive vs Negative) | 3.518        | 0.0607 |
| Post-operative radiation therapy (Yes vs No)  | 0.082        | 0.7739 |
| Tumour-survivin mRNA expression (High vs Low) | 6.154        | 0.0313 |

**DISCUSSION**

The role of survivin protein is unique, having been shown to bind specifically to caspases-3 and -7 and to inhibit apoptosis in *in vitro* system (Tamm *et al.*, 1998). Furthermore, Li *et al.* (1998) reported that survivin expression during the G2/M phase of the cell cycle and the disruption of survivin-microtubule interactions results in increased caspase-3 activity and accelerated apoptotic cell death. Ito *et al.* (2000) reported that hepatocellular carcinoma cell lines transfected with survivin show a significant decrease in cells in the G0/G1 phase and an increase in cells in the S and G2M phases. These findings indicate that survivin protein expression may correlate not only with reduced apoptotic cell death but also with an increased proliferative activity of cancer cells. Recently, the clinical importance of survivin mRNA expression has been reported in various cancers. These reports demonstrated that the prognosis of patients with survivin mRNA expression positive tumours was significantly worse than that of patients with survivin negative.

The reports noted above were based on the RT–PCR method, while in the present study we used real-time RT–PCR to evaluate the quantitative expression levels of survivin mRNA in oesophageal tissues instead of either the RT–PCR or Northern blot methods. The expression levels of GAPDH (internal control) mRNA were reported to be quite different among samples, even when the same amounts of total RNAs were used (Suzuki *et al.*, 2001). This phenomenon might be overlooked in Northern blot or RT–PCR assay. Moreover, Northern blot requires many complicated techniques such as gel electrophoresis, membrane transfer, and hybridisation and requires a comparatively long time to obtain results. Also, it is difficult to estimate the real amount of gene expression level by a RT–PCR method. The recent development of real-time RT–PCR technology has made reliable and accurate PCR quantification possible. This technology monitors the entire PCR reaction by fluorescence detection, thereby allowing the beginning of the exponential phase of amplification (threshold cycle) to be measured. This reaction point is considered the most reliable point of the PCR reaction relative to sample concentration (Wittwer *et al.*, 1997).

Using real-time RT–PCR method, we found that the mean survivin mRNA expression level of non-cancerous oesophageal tissues (the normalised amounts of survivin mRNA were determined by dividing the amounts of mRNA levels by the amount of GAPDH mRNA for each sample) was 3.6. Kato *et al.* (2001) reported that survivin mRNA expression of normal oesophageal tissues detected by RT–PCR method was observed in 47.1% of cases and that this rate was higher than that of normal lung tissues (12%) or that of normal colorectal tissues (29.1%). It is well known that esophageal epithelium has rapid renewal (Takubo *et al.*, 1997). These findings indicate that survivin mRNA may express with high proliferative activity even in normal tissues.

Our results demonstrated that tumour-survivin mRNA expression level did not correlate with lymph node metastasis or depth...
survivin mRNA in oesophageal cancer
M Ikeguchi and N Kaibara

M molecular and cellular pathology

REFERENCES

Adica D, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43–49

Asanuma K, Mori K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N (2000) Survivin as a radiosensitivity factor in pancreatic cancer. Jpn J Cancer Res 91: 1204–1209

Azahata T, Scott D, Takamizawa S, Watanabe N, Davidoff A, Fukuwaza M, Sandler A (2001) The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. Pediatr Surg 36: 1785–1791

Cheung SY, Cheung N-KV (2001) Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 7: 1698–1705

Clem RJ, Miller LK (1994) Control of programmed cell death by the baculovirus genes p53 and iap. Mol Cell Biol 14: 5212–5222

Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Nien dorff A, Knoefel WT, Izbicki JR (2001) Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 19: 1970–1975

Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N (2000) Clinical significance of retinoblastoma protein (pRb) expression in esophageal squamous cell carcinoma. J Surg Oncol 73: 104–108

Ikeguchi M, Liu J, Kaibara N (2002) Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 7: 23–29

Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama Y, Kawanoh H, Hayashida M, Nakano T, Suzuki A (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31: 1080–1085

Kato J, Kwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95: 92–95

Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580–583

Maholtra C, Wenzel M, Springer E, Gabbert HE, Gerharz CD (1999) Survivin-ΔEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097–6102

Mitas M, Mihktarian K, Walters C, Baron PC, Elliott BM, Brothers TE, Robinson JG, Mctelfast JS, Palesch YY, Zhang Z, Gillanders WS, Cole DJ (2001) Quantitative real-time RT–PCR detection of breast cancer micro-metastasis using a multigene marker panel. Int J Cancer 93: 162–171

Monzo M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A (1999) A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. J Clin Oncol 17: 2100–2104

Sarbia M, Stahl M, Fink U, Heep H, Duttkowski P, Willers R, Seebel S, Gabbert HE (1999) Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer 84: 86–91

Sarela AJ, Macadam RCA, Farmery SM, Markham AF, Guilou PJ (2000) Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma. Gut 46: 645–650

Suzuki R, Takemura K, Tsutsumi M, Nakamura S, Hamajima N, Seto M (2001) Detection of cyclin D1 overexpression by real-time reverse-transcriptase-method quantitative polymerase chain reaction for the diagnosis of mantle cell lymphoma. Am J Pathol 159: 425–429

Tachibana M, Kinugasa S, Dhar DK, Tabara H, Masunaga R, Kotoh T, Kubota H, Nagaune N (1999) Prognostic factors in T1 and T2 squamous cell carcinoma of the thoracic esophagus. Arch Surg 134: 50–54

Takubo K, Nakamura K, Izumiya N, Mafune K, Tanaka Y, Miyashita M, Sasajima K, Kato M, Oshimura M (1997) Telomerase activity in esophageal carcinoma. J Surg Oncol 66: 88–92

Tammi I, Wang Y, Sauville E, Scudiero DC, Vigna N, Oltersdorf T, Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95). Bax, Caspases, and anticancer drugs. Cancer Res 58: 5315–5320

Wen SF, Xie L, McDonald D, DiGiacomo R, Chang A, Gurmani M, Shb B, Liu S, Indelicato SR, Hutchins B, Nielsen LL (2000) Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Cancer Gene Therapy 7: 1469–1480

Wittwer CT, Hermann MG, Moss AA, Rasmussen RP (1997) Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22: 130–138

Yajima T, Yagihashi A, Kameshima H, Kobayashi D, Furuya D, Hirata K, Watanabe N (1998) Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 44: 2441–2445

of tumour invasion in OSCC. The same result has been observed in colorectal carcinoma (Sarela et al, 2000) and in non-small-cell lung cancer (Monzo et al, 1999). These findings indicate that tumour- survivin mRNA expression level may not correlate with metastatic potential of tumour cells.

However, in previous studies, and in ours, patients who had tumours with high survivin mRNA expression revealed shorter survival. Recently, it has been shown that pancreatic cancer cells or gastric cancer cells with strong survivin mRNA expression showed a chemo-radiosensitivity in vitro (Asanuma et al, 2000; Ikeguchi et al, 2002). Moreover, from a clinical perspective, patients with survivin mRNA positive tumours showed chemo-radiosensitivity in OSCC (Kato et al, 2001). In a study of neuroblastoma (Azuhata et al, 2001), and in our study of OSCC, tumour-survivin mRNA expression showed strong positive correlations with the tumour recurrence of patients. From these results, it is suggested that micrometastatic foci with strong survivin mRNA expression may have high proliferative activity and may increase rapidly and also may acquire resistance to adjuvant chemo-radiotherapy.

We conclude that survivin mRNA expression may become a useful prognostic biomarker in OSCC and the quantitative real-time RT–PCR method is a useful technique for determining gene expression levels in tissue.